Cancer has become one of the main public issues threatening human health around the world. According to the latest global cancer burden data released by the International Agency for Research on Cancer (IARC) of the World Health Organization in 2020, there were 19.29 million new cancer cases and 9.96 million deaths worldwide in 2020. Among them, the number of cancers in China accounted for 49.3% of the world’s total, and China’s deaths accounted for 58.3% of the world’s total. The “Cancer Statistics Report 2020” released by the American Cancer Society (ACS) shows that from 2009 to 2015, the overall 5-year survival rate for all cancers in the United States was 67%, which is still relatively significant compared to my country’s 40.5%. There are huge vacancies waiting to be filled in cancer diagnosis, treatment, drug development, and health management.
Artificial Intelligence (AI) can help collect a large amount of medical data, quickly calculate, reduce redundant work, and provide more accurate diagnosis and treatment plans, help reduce the gap between hospitals at all levels, and promote excellent medical treatment and resources. Shenhe hierarchical diagnosis and treatment helps reduce the cost and time of drug development by about one-third. The electronicization of medical information in my country has been basically completed, but the core functions of medicine, including diagnosis, treatment, and drug research and development, require high thresholds for medicine and artificial intelligence, and it is still in the initial stage.
Shihua Medical develops internationally leading multi-gene, multi-factor and multi-omics technology, focusing on solving the intelligent problems of medical diagnosis, treatment and drug research and development. Dr. Xing Chuanhua, founder of Shihua Medical, said: “The occurrence and development of diseases are caused by the interaction of multiple genes and multiple pathogenic factors. However, the existing sequencing and interpretation still remain at the one-to-one match between a single gene and database information, and genetic testing cannot To answer the relationship between disease and genes, clinical single genes are less than 10% of all disease-causing genes, and most genes related to complex diseases have not been used clinically.” However, I want to clarify the relationship between disease and each gene locus. , Relying on manpower is far from enough. Therefore, Shihua Medical integrates multi-source information such as microorganisms, images, cells, methylation, and immune markers through international leading AI technology and disruptive algorithms, and has developed products such as intelligent gene diagnosis, clinical decision-making, and intelligent auxiliary drug research and development. , Which can achieve earlier, more accurate, more efficient, and lower-cost cancer diagnosis, help high-risk cancer patients achieve precise diagnosis and treatment, find suitable targeted drugs and the best treatment plan for patients, and open up a new generation of cancer diagnosis and treatment And decision path.
Multi-gene, multi-factor and multi-omics, opening up a new situation in cancer diagnosis and treatment
In 2001, Xing Chuanhua went to study in the United States, under the tutelage of Professor Donald Bitzer, a master of machine algorithms and an academician of the American Academy of Engineering. “At that time, Dr. Craig Venter had just completed the first human whole-genome sequencing with his own genes. The fascination for deciphering human genes and diseases prompted me to choose this unpopular major as my doctoral research direction, and machine algorithms deeply mine genomics and clinical data. “Graduated from North Carolina State University and a postdoctoral fellow at Duke University. Dr. Xing successively served as an assistant professor at Boston University, a visiting professor at Sun Yat-sen University, the head of AstraZeneca R&D, and the American Chinese Biomedical Technology Association (www.cba-usa). .org) 2019-2020 President, etc., cooperated with many winners of COPSS Presidents’Award, the highest award of statistical machine algorithm, and one of the technical leaders of major precision medicine and genomics projects in the United States, including AstraZeneca’s non-small cell lung cancer PD -1/PL-L1 Imfinzi immunologic drugs, The Framingham Heart Study and the CHARGE Sequencing, etc., has been the special guest of domestic and foreign industry conferences, accepted interviews, and won international awards including IFAH 2021 the Top 100 Healthcare Visionaries Award.
In 2015, based on years of deep accumulation in the field of cancer AI diagnosis and treatment, Dr. Xing Chuanhua founded XPrecision in the United States, and completed the pre-development and preliminary clinical verification of cancer AI diagnosis and treatment technology. Recently, Dr. Xing Chuanhua returned to China and founded Shihua Medical, starting the commercialization and further development of cancer AI diagnosis and treatment technology.
Dr. Xing Chuanhua said: “Although I have studied and worked in the United States for many years, I was born in China and grew up in China, and I have an indispensable feeling for my motherland. In recent years, China’s medical innovation and entrepreneurship environment has gradually improved. In particular, AI technology is becoming more and more popular, so I am very willing to return to China to start a business, promote the development of domestic AI medical care, and contribute to the fight against cancer and the health of people in China and the world.”
Participating in the early creation of Shihua Medical is Dr. Yong Wang, an international expert on intelligence and automation, serving as the CTO of Shihua Medical. Dr. Wang Yong is a Ph.D student of Dr. Xing Chuanhua, a graduate with a perfect GPA in machine algorithm and big data optimization. Dr. Wang Yong works in the world’s top commercial data software company, specializing in the development of big data solutions for the world’s top 100 companies, and has 20 years of experience in commercial big data system architecture and software development. His existence guarantees Shihua Medical’s international leadership in intelligent and automated development.
Dr. Tiange Cui is the chief scientist of Shihua Medical, responsible for Shihua Medical’s bioinformatics research and development and product development. As early as three years ago, Dr. Cui Tiange and Dr. Xing had many exchanges on the topic of intelligent cancer diagnosis and treatment. Upon learning that Shihua Medical was founded, Dr. Cui Tiange resolutely joined the company to promote the development of intelligent cancer diagnosis and treatment technology. Dr. Tiange Cui graduated from George Mason University majoring in Letters and Computing. He has been employed by a number of well-known biomedical companies including Regeneron (Regeneron Pharmaceuticals), Vertex (Vertex Pharmaceuticals), and Sangamo Therapeutics, an American gene editing company. Cofactor Genomics participated in the development of the first immunosuppressant drug companion diagnostic kit. He has many years of research and development experience in high-throughput sequencing, cancer genomics, viral genomics, gene editing and cell therapy and other related bioinformatics and translational medicine fields, and has developed a variety of bioinformatics software products.
It is understood that compared with the existing genetic testing solutions, the cancer AI diagnosis and treatment solution developed by Shihua Medical breaks the current one-to-one matching of single gene and database information, and for the first time in the history of algorithms, any independent and partial components have been removed. Independent assumptions retain all dependencies of data, and can capture the combined effects of high-dimensional genes/factors on diseases at the same time, and integrate genes, microorganisms, images, immune markers, methylation, clinical information and other multi-genes through AI. Multi-omics information is used to maximize the capture of cancer signals, diagnose cancer earlier and more accurately, reduce costs, and empower early cancer screening, late treatment, and drug development.
For early cancer screening, Shihua Medical is developing solutions for early screening and diagnosis of gynecological tumors, upper gastrointestinal cancer and pan-cancer species, using AI-driven multi-gene and multi-factor models to detect whether patients have cancer and reduce cancer morbidity and mortality. . In the diagnosis and treatment of advanced cancer, Shihua Medical’s development of gynecological tumors, upper gastrointestinal cancer and pan-cancer diagnosis and treatment technologies can recommend the best treatment plan for patients, reduce the recurrence rate, improve the survival rate, and discover new cancer targets for use L.
Confirmation experiments show that Shihua Medical’s machine algorithm maintains a stable and high accuracy rate in various complex data tests. Its cancer AI diagnosis and treatment technology has an accuracy rate of at least 20% higher than that of the most popular method, and it is in phase I and phase II. In cancer, the company’s early screening and early diagnosis model has an accuracy rate of 10%-20% higher than similar products, which can significantly improve the level of early cancer screening in China, increase the five-year survival rate after cancer diagnosis from 30% to 70%, and extend the number of patients. The life span is 5-10 years. Relying on its outstanding performance in the cancer AI diagnosis and treatment industry, soon after its establishment, Shihua Medical quickly completed the construction of its core team and began the construction of the kilometer laboratory in the Suzhou Industrial Park. Medical Technology Co., Ltd., Leapsun Medical, etc. reached a cooperation, established a R&D team in the United States, and was recommended by the Suzhou Industrial Park leader and major projects. Dr. Xing also just won the International IFAH the Top 100 Healthcare Visionaries Award in Las Vegas, the United States .
The potential of AI in the cancer diagnosis and treatment circuit is immeasurable
Medical treatment is considered to be one of the largest application areas of AI. At present, AI has already shined in subdivision tracks such as surgical robots, smart devices, and image recognition. The research and development of AI drugs has also shown a rapid growth trend recently, but the development of technology and market is still in its infancy. As an emerging direction, intelligent omics has begun to move from the forefront of scientific research to industry and clinical, using advanced AI machine algorithms to deeply mine omics, including genomics, transcriptome, proteomics and metabolomics, etc., to develop diagnosis, treatment and drug research and development. And other products and applications. After 20 years of rapid development in intelligent omics technology, whether it is from gene mining or medical intelligence, the market has strong demand and broad prospects and exponential growth. According to the industry survey of the 2019 Medical and Health Industry Data View Series | Clinical Application of Genetic Testing Market Analysis (Part 2), the penetration rate of the genetic testing market will increase to 30-40% by 2025, which is more than 30 times the current level. “In the future, companies that can solve the industry’s pain points, master core technologies, and promote industry standardization will grow into the leaders of the next stage of the industry!” said Dr. Xing.
Based on the multi-gene technology to promote the multi-gene, multi-factor and multi-omics systematic medical method, Shihua Medical is unique and promotes new market growth points. Dr. Xing Chuanhua believes that, on the whole, the potential market capacity of the cancer AI diagnosis and treatment track where Shihua Medical is located is in the hundreds of billions, which is worthy of deep cultivation. She said: “I have explored the field of AI diagnosis and treatment for more than 20 years. Although we have not seen the end of the road to overcome cancer, AI can maximize the potential of cancer diagnosis and treatment and will make a non-negligible contribution to solving cancer problems. .”
In recent years, major sequencing companies and capitalists in the industry have been paying attention to the direction of AI genomics, and domestic and foreign projects focusing on mining omics have also increased rapidly. In February this year, sequencing giant Illumina and Red Shirt Capital cooperated to launch China’s smart medical care in Shanghai. Genomics incubator, AI genomics has always been a hot topic for discussion in major forums and conferences. AI will continue to optimize the accuracy, cost, and efficiency of cancer early screening, diagnosis and treatment, and drug research and development. AI genomics will definitely be a track that quickly becomes hot.
As an early promoter of cancer AI diagnosis and treatment technology, Dr. Xing Chuanhua will lead Shihua Medical to quickly complete the clinical application of early screening and early diagnosis of gynecological tumors and early screening and early diagnosis of upper gastrointestinal cancer, and launch LDT services. At the same time, the diagnostic intelligence and automated AI software system developed by the company will be launched soon, which can automate the entire process of genetic testing. In the coming days, Shihua Medical will work with the industry to promote the development of cancer AI diagnosis and treatment in China and the world, and solve the diagnosis and treatment of major diseases that threaten human health.